AlphaStar Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

AlphaStar Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-445	Closed	-$207K	–	380
2024 Q3	$207K	Sell	445 -76	-15%	-$36.5K	0.02%	355
2024 Q2	$244K	Sell	521 -100	-16%	-$43.4K	0.02%	280
2024 Q1	$260K	Sell	621 -178	-22%	-$75.2K	0.03%	250
2023 Q4	$325K	Sell	799 -837	-51%	-$309K	0.03%	223
2023 Q3	$569K	Buy	+1,636	New	+$572K	0.07%	164
2022 Q2	–	Sell	-5,964	Closed	-$1.56M	–	403
2022 Q1	$1.56M	Buy	5,964 +300	+5%	+$71.2K	0.13%	127
2021 Q4	$1.33M	Buy	+5,664	New	+$1.1M	0.11%	147

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

AlphaStar Capital Management's VRTX Position: Q4 2024 in Review

AlphaStar Capital Management sold out of Vertex Pharmaceuticals (VRTX) in Q4 2024, closing a stake of 445 shares — an estimated $207K sold.

AlphaStar Capital Management first reported a position in VRTX in Q4 2021 and held it in 7 quarters. The position peaked at $1.56M in Q1 2022. 1,557 funds tracked by Wall St. Rank hold VRTX as of Q4 2024.

AlphaStar Capital Management reported no remaining Vertex Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
AlphaStar Capital Management sold 445 Vertex Pharmaceuticals shares in Q4 2024, an estimated $207K.
AlphaStar Capital Management first reported a position in Vertex Pharmaceuticals in Q4 2021 and held it in 7 quarters.
AlphaStar Capital Management's Vertex Pharmaceuticals position peaked at $1.56M in Q1 2022.
1,557 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2024.

Based on AlphaStar Capital Management's 13F filing for Q4 2024, filed 28 Jan 2025.